Wilson James N: insider trades.
Wilson James N reported 10 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($3.1M), across 1 company.
- Transactions
- 10
- Purchases (P)
- 0
- Sales (S)
- 10
- Companies
- 1
- Name as filed
- WILSON JAMES N
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Corcept Therapeutics Inc (CORT) | Director | 10 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-15 | Corcept Therapeutics Inc | S | 2,800 | $111.7 | 1,064,543 | Form 4 |
| 2026-09-15 | Corcept Therapeutics Inc | S | 400 | $110.84 | 1,067,343 | Form 4 |
| 2026-09-15 | Corcept Therapeutics Inc | S | 6,800 | $110.27 | 1,067,743 | Form 4 |
| 2026-08-14 | Corcept Therapeutics Inc | S | 3,053 | $110.49 | 1,081,490 | Form 4 |
| 2026-08-14 | Corcept Therapeutics Inc | S | 2,279 | $112.64 | 1,074,543 | Form 4 |
| 2026-08-14 | Corcept Therapeutics Inc | S | 4,668 | $111.44 | 1,076,822 | Form 4 |
| 2026-07-15 | Corcept Therapeutics Inc | S | 1,079 | $86.78 | 1,093,464 | Form 4 |
| 2026-07-15 | Corcept Therapeutics Inc | S | 3,969 | $87.74 | 1,089,495 | Form 4 |
| 2026-07-15 | Corcept Therapeutics Inc | S | 1,978 | $89.49 | 1,084,543 | Form 4 |
| 2026-07-15 | Corcept Therapeutics Inc | S | 2,974 | $88.81 | 1,086,521 | Form 4 |
Questions
What stock did Wilson James N buy or sell?
Wilson James N reported 10 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($3.1M), across 1 company.
Is Wilson James N the same person as other filers with this name?
This page covers SEC CIK 1236387 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/wilson-james-n-1236387.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.